Reactive hypoglycemia is not considered to present without symptoms accompanying low blood glucose (i.e., you cannot just have low blood glucose)
GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) effectively manage type 2 diabetes and promote weight loss, but their gastrointestinal effectsincluding nausea, vomiting, and diarrheacan disrupt fluid and electrolyte balance
The SURMOUNT-4 data showed that cardiometabolic markers deteriorated in proportion to weight regain, so these labs serve as an early warning system
Add on pricing is typically lower than a standalone infusion but still reflects the dose used and the additional preparation required
Oily stools, fecal urgency, oily spotting on undergarments, and flatulence with discharge affect up to 79% of users in clinical trials